Yunnan Baiyao's (SHE:000538) INB301 Injection obtained clearance from the U.S. Food and Drug Administration to conduct clinical trials for treating cancer cachexia.
Cancer cachexia is a complex metabolic disorder characterized by persistent muscle wasting, according to a Thursday filing with the Shenzhen bourse.
Shares of the drug manufacturer closed 1% lower Thursday.